Study drug RMC-9805 for patients with KRAS G12D solid tumors (RMC-9805-001)

Study drug RMC-9805 for patients with KRAS G12D solid tumors (RMC-9805-001)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out if an investigational drug called RMC-9805 (the study drug) is a safe and effective option for treating KRAS G12D mutated cancer. We are also trying to figure out what dose of the study drug works best for most people.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Have solid tumor(s) that are locally advanced or metastatic
  • Have a documented KRAS G12D mutation
  • Have worsened following standard therapy
For more information about who can join this study, contact the study team at 919-668-1861.

What is Involved?

Description

If you choose to join this study, you will:
  • Take the study drug by mouth every day
  • Have your tumor biopsied
  • Give blood and urine samples
  • Have regular CT or MRI scans

Study Details

Full Title

[RMC-9805-001] Phase 1/1b, multicenter, open-label, study of RMC-9805 in participants with advanced KRASG12D-mutant solid tumors

Principal Investigator

John
Strickler

Protocol Number

PRO00114818

NCT ID

NCT06040541

Phase

I

Enrollment Status

Open to Enrollment
ClinicalTrials.gov